| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543780903535867 |
| P698 | PubMed publication ID | 20113217 |
| P2093 | author name string | Matthias K Schwarz | |
| Christine A Power | |||
| Amanda E I Proudfoot | |||
| P2860 | cites work | HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 |
| Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
| Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes | Q22253300 | ||
| Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. | Q40364641 | ||
| Proteolytic activation of alternative CCR1 ligands in inflammation | Q40419745 | ||
| Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis | Q40643961 | ||
| Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1. | Q40671961 | ||
| Exacerbations of multiple sclerosis in patients treated with gamma interferon | Q40797798 | ||
| Design, synthesis, and discovery of a novel CCR1 antagonist | Q40811774 | ||
| Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor | Q41032296 | ||
| Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration | Q42543239 | ||
| Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice | Q43489161 | ||
| Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease. | Q44598110 | ||
| Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis | Q46897070 | ||
| The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice | Q46956212 | ||
| Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study | Q47927665 | ||
| Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. | Q51830522 | ||
| Inhibition of fractalkine ameliorates murine collagen-induced arthritis. | Q54692528 | ||
| Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene | Q56591978 | ||
| Blockade of chemokine signaling in patients with multiple sclerosis | Q57623592 | ||
| Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6C hi and Ly6C lo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice | Q58149069 | ||
| Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis | Q58443833 | ||
| Molecular cloning and functional expression of a new human CC-chemokine receptor gene | Q24313022 | ||
| Structure and Functional Expression of a Human Interleukin-8 Receptor | Q24319897 | ||
| Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients | Q24563395 | ||
| Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) | Q24641929 | ||
| Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor | Q24680555 | ||
| Chemokines and disease | Q28200068 | ||
| Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor | Q28297700 | ||
| A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen | Q28300225 | ||
| Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1 | Q28375207 | ||
| Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development | Q28512895 | ||
| Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis | Q28755978 | ||
| Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
| Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 | Q29616092 | ||
| HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 | ||
| Chemokines--chemotactic cytokines that mediate inflammation | Q29616433 | ||
| Review of progressive multifocal leukoencephalopathy and natalizumab | Q31079746 | ||
| MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. | Q33844451 | ||
| The toxicology of chemokine inhibition. | Q34453072 | ||
| Chemokine receptors: multifaceted therapeutic targets | Q34575325 | ||
| New therapeutics that modulate chemokine networks | Q34743328 | ||
| Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines | Q34762409 | ||
| Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis | Q35553008 | ||
| CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. | Q35788387 | ||
| Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. | Q36368947 | ||
| CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin | Q36370073 | ||
| CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions | Q36384816 | ||
| Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis | Q36660105 | ||
| Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury | Q37079501 | ||
| Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls | Q37142643 | ||
| Chemokines and leukocyte traffic | Q37246677 | ||
| Chemokine receptor antagonists: overcoming developmental hurdles | Q37349685 | ||
| Chemokines and chemokine receptors: an overview. | Q37409994 | ||
| Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. | Q37415334 | ||
| A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis | Q39763545 | ||
| Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial | Q39850979 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 345-355 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Anti-chemokine small molecule drugs: a promising future? | |
| P478 | volume | 19 |
| Q42764236 | A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators |
| Q27308798 | A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy |
| Q46475805 | Another chemokine target bites the dust? |
| Q37118156 | Anti-inflammatory Agents: Present and Future |
| Q51601857 | Are we just learning the scales on the chemokine receptor pianos? |
| Q37860347 | Biological therapies in primary Sjögren's syndrome. |
| Q39173890 | CC chemokine ligand 2 and CXC chemokine ligand 8 as neutrophil chemoattractant factors in canine idiopathic polyarthritis. |
| Q36980670 | CCR6 as a possible therapeutic target in psoriasis |
| Q35849570 | Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation |
| Q38172960 | Chemokine receptor modeling: an interdisciplinary approach to drug design |
| Q33810517 | Chemokine receptor oligomerization and allostery |
| Q38144211 | Chemokine receptors in psoriasis |
| Q47154563 | Chemokines from a Structural Perspective |
| Q38018862 | Chemokines in CNS injury and repair |
| Q52315330 | Complex role of chemokine mediators in animal models of Alzheimer's Disease. |
| Q35550241 | Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms |
| Q37819144 | Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. |
| Q38827574 | Elucidation of the CCR1- and CCR5-binding modes of MIP-1α by application of an NMR spectra reconstruction method to the transferred cross-saturation experiments |
| Q33763369 | Emerging concepts and approaches for chemokine-receptor drug discovery |
| Q43216438 | Evasin-displaying lactic acid bacteria bind different chemokines and neutralize CXCL8 production in Caco-2 cells |
| Q36194247 | Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes. |
| Q37115195 | Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development |
| Q37803119 | Functional role of chemokines in liver disease models |
| Q37944472 | Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? |
| Q34066497 | G protein signaling modulator-3: a leukocyte regulator of inflammation in health and disease |
| Q34290999 | Genetic identity and biological phenotype of a transmitted/founder virus representative of nonpathogenic simian immunodeficiency virus infection in African green monkeys |
| Q37991389 | Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents |
| Q38796479 | Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5). |
| Q34153125 | Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation |
| Q93088634 | NFATc3 controls tumour growth by regulating proliferation and migration of human astroglioma cells |
| Q36606727 | Nematode asparaginyl-tRNA synthetase resolves intestinal inflammation in mice with T-cell transfer colitis |
| Q45087012 | Novel challenges for the allergist |
| Q42771123 | Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity |
| Q46441158 | Overcoming hurdles in developing successful drugs targeting chemokine receptors |
| Q37812614 | Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor |
| Q45999111 | Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. |
| Q37893687 | Pharmacological modulation of chemokine receptor function. |
| Q38083321 | Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012. |
| Q27694728 | Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior |
| Q38114832 | Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases |
| Q45365916 | Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model |
| Q37925018 | Targeting inflammation in cardiovascular diseases. still a neglected field? |
| Q50998405 | The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis. |
| Q26824492 | The chemokine superfamily revisited |
| Q37869047 | The complex world of oligodendroglial differentiation inhibitors |
| Q42208932 | The role of chemokines in acute liver injury |
| Q37989141 | The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. |
| Q34060799 | The yin and yang of chemokine receptor activation |
| Q34445135 | Therapeutic antibodies directed at G protein-coupled receptors |
| Q37960533 | Therapeutic potential of chemokine receptor antagonists for liver disease |
| Q38680670 | What Do Structures Tell Us About Chemokine Receptor Function and Antagonism? |
Search more.